子宫腺肌病 中国就医指南

Adenomyosis is a common, benign gynecological disorder characterized by the ectopic presence of endometrial glands and stroma within the myometrium—the muscular layer of the uterus. Unlike endometriosis, which involves endometrial-like tissue outside the uterus, adenomyosis represents an inward invasion, leading to uterine enlargement, diffuse or focal myometrial thickening, and often significant clinical symptoms. The exact pathogenesis remains incompletely understood but is thought to involve abnormal tissue repair following uterine trauma (e.g., childbirth, cesarean delivery, or uterine surgery), hormonal dysregulation—particularly estrogen-dependent proliferation—and possible stem cell migration from the basalis endometrium into the myometrium. Recent evidence also implicates chronic inflammation, immune dysfunction, and aberrant Wnt/β-catenin signaling in disease initiation and progression. Epidemiologically, adenomyosis affects an estimated 20–35% of reproductive-age women, though prevalence rises sharply with age—reaching up to 60–70% in women undergoing hysterectomy for symptomatic indications. It is frequently underdiagnosed due to overlapping symptoms with fibroids or endometriosis and limitations of conventional imaging; definitive diagnosis historically required histopathology post-hysterectomy, though high-resolution transvaginal ultrasound (TVUS) with expert sonographic criteria and MRI now enable non-invasive diagnosis with >90% sensitivity and specificity in specialized centers. Key risk factors include parity (especially vaginal delivery and cesarean section), prior uterine surgery (e.g., myomectomy, D&C), mid-to-late reproductive age (peak incidence 40–50 years), and possibly genetic predisposition. Notably, nulliparity does not exclude adenomyosis, and increasing numbers of cases are being identified in younger, childbearing women—including those with infertility or recurrent implantation failure. Clinically, adenomyosis profoundly impacts quality of life: heavy menstrual bleeding (menorrhagia) leads to iron-deficiency anemia, fatigue, and reduced work productivity; severe dysmenorrhea (often progressive and unresponsive to NSAIDs) disrupts daily functioning and sleep; chronic pelvic pain and deep dyspareunia strain intimate relationships; and infertility or recurrent pregnancy loss contributes to psychological distress, anxiety, and depression. Many patients report diminished sexual health, social withdrawal, and impaired emotional well-being—factors rarely captured in routine clinical assessments but critical to holistic management. Early recognition and individualized, multidisciplinary care—integrating reproductive endocrinology, minimally invasive surgery, pain medicine, and mental health support—are essential to mitigate long-term morbidity and preserve fertility when desired.

# 子宫腺肌病治疗方案与费用明细（生殖医学科）

一、非手术保守治疗

• •适用人群：有生育需求、症状轻中度、无严重贫血或盆腔粘连者
• •药物方案：

- 二线（GnRH-a针剂）：单支1,200–2,500元，3–6针为一疗程（含骨密度监测+反向添加），总费用4,500–16,000元；

• •检查费：盆腔超声（300–500元）、CA125（80元）、性激素六项（300元）、MRI（800–1,200元）

二、手术与介入治疗

• •宫腔镜病灶切除术（保留子宫）：适用于局灶型、合并不孕者；术前检查2,000元，手术+麻醉+住院（5–7天）总费用18,000–28,000元；
• •高强度聚焦超声（HIFU）：微创无创，适合中重度但暂不生育者；单次治疗12,000–18,000元（含术前MRI评估及术后随访）；
• •根治性手术（全子宫切除）：仅用于无生育要求、症状顽固、合并腺肌瘤≥5cm者；总费用35,000–52,000元（含腹腔镜/开腹路径、病理、住院8–10天）。

三、复杂/耐药/晚期方案

• •多线药物失败+合并不孕：推荐“GnRH-a预处理+宫腔镜联合IVF助孕”，全程费用约65,000–95,000元；
• •广泛弥漫型+重度痛经+贫血：需多学科协作（妇科+血液科+疼痛科），年综合管理费25,000–40,000元。

四、方案快速选择指南

• •预算≤2万+有生育计划 → 地诺孕素+宫腔镜评估；
• •预算3–5万+拒绝手术 → HIFU联合IVF周期规划；
• •无生育需求+症状严重影响生活 → 腹腔镜辅助子宫切除；
• •反复治疗无效+合并不孕 → GnRH-a预处理后转生殖中心个体化助孕。